PLYX Polaryx Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2075320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-114.9%
ROA-101.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.6%
Debt / equity0.00x
Current ratio8.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $6.27M | $2.81M |
| SG&A expense | $1.55M | $1.54M |
| Operating income | -$7.82M | -$4.35M |
| Pretax income | -$8.98M | -$30.36M |
| Net income | -$8.98M | -$30.36M |
| EPS (basic) | -0.20 | -0.89 |
| EPS (diluted) | -0.20 | -0.89 |
| Weighted avg. shares (diluted) | 45.42M | 34.20M |
| Balance sheet | ||
| Cash & equivalents | $5.14M | $4.62M |
| Current assets | $5.17M | $5.00M |
| Total assets | $5.17M | $5.00M |
| Current liabilities | $605,000 | $289,000 |
| Total liabilities | $605,000 | $289,000 |
| Shareholders' equity | $4.57M | $4.71M |
| Shares outstanding | 47.34M | 41.15M |
| Cash flow statement | ||
| Operating cash flow | -$3.94M | -$2.57M |
| Financing cash flow | $4.47M | $7.19M |
| Stock-based compensation | $4.72M | $2.40M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.